Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 89 of 6351
-
Two-Drug combo aims to wipe out childhood leukemia faster
Disease control Recruiting nowThis is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To a…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for high-risk MDS: phase 3 trial of lisaftoclax combo launches
Disease control Recruiting nowA global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can AI read tumor slides to outsmart childhood cancer?
Diagnosis CompletedPediatric malignancies are the second leading cause of death in the pediatric population, with solid tumors accounting for approximately 60% of all pediatric malignancies. The pathological diagnosis of pediatric solid tumors is highly complex and specialized, because of its diver…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tough colon cancer: drug cocktail boosts surgery success
Disease control Recruiting nowNeoadjuvant immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, for patients with mismatch repair-proficient or microsatellite stable (pMMR/MSS) CRC, the efficacy of P…
Phase 3 • Sponsor: Jun Huang • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
Disease control Recruiting nowPhase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).
Phase 3 • Sponsor: Federal University of Health Science of Porto Alegre • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a 2-Month TB cure replace 6 months of pills for kids?
Disease control Recruiting nowWhile drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as e…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can some breast cancer patients safely skip extra radiation?
Disease control Recruiting nowThis is an open-label, multicenter, randomized phase 3 trial. Eligible patients are women with cN3 breast cancer who have completed neoadjuvant systemic therapy (NST), undergone breast/axillary surgery with the internal mammary, supraclavicular, and infraclavicular nodes left und…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
CRISPR therapy takes on rare swelling disorder
Disease control OngoingThis Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Personalized cell therapy takes on advanced melanoma in major trial
Disease control Recruiting nowThis clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choi…
Phase 3 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for kids with rapid-aging disease: drug combo tested
Disease control OngoingResearchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take th…
Phase 2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can artificial intelligence make lung cancer staging more accurate?
Diagnosis Recruiting nowLung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it aids in treatment decisions - whether a patient is …
Sponsor: McMaster University • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
One-Time gene fix could ease PKU's strict diet burden
Disease control Recruiting nowThis is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Pa…
Phase 1/2 • Sponsor: NGGT INC. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug GQ1005 takes on T-DM1 in advanced HER2-Positive breast cancer
Disease control Recruiting nowThis study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
Phase 3 • Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle tough childhood leukemia
Disease control Recruiting nowTo evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.
Phase 3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Absorbable 3D-Printed splint could save kids with rare breathing disorder
Disease control Recruiting nowThe purpose of this study is to learn if a three-dimensional (3D) printed airway splint device made to hold open a collapsing airway is a safe and effective treatment of Tracheobronchomalacia (TBM) in children. The airway splint is bioresorbable, meaning the child's body will ab…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Rectal cancer breakthrough: could a new drug combo save your rectum?
Disease control Recruiting nowThis study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complicat…
Phase 2/3 • Sponsor: National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could chilling the body after cardiac arrest save more brains?
Disease control Recruiting nowThe SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation f…
Sponsor: Kagawa University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new immune therapy help frail lung cancer patients live longer?
Disease control Recruiting nowThe SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2). The study will include 57 participants at about 15 sites in…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
AI eye scanner could prevent blindness in millions with diabetes
Diagnosis Recruiting nowIn this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of …
Sponsor: iHealthScreen Inc • Aim: Diagnosis
Last updated Jun 26, 2026 12:53 UTC